Agenus INC DEF 14A proxy statements

Agenus Inc. outlines 2025 clinical progress, a strengthened balance sheet, and key equity proposals for the 2026 Annual Meeting.

Agenus Inc. is seeking stockholder approval to significantly expand its equity incentive plan and implement a one-time option exchange program to address challenges stemming from a negative FDA recommendation, stock price decline, and ongoing SEC investigation.

Agenus Inc. files an amendment to its definitive proxy statement to correct the number of outstanding common stock shares as of the record date.

Agenus is asking stockholders to approve amendments to its equity incentive plans and a one-time option exchange to enhance employee retention and align interests amid financial challenges.

Agenus Inc. is asking stockholders to approve amendments to its equity incentive plan and directors' deferred compensation plan at the upcoming annual meeting.

Agenus Inc. has amended its proxy statement to clarify the voting requirements for the proposed reverse stock split at the upcoming Special Meeting of Stockholders.